Johnson & Johnson
JNJ-N
177 watching
About Johnson & Johnson (JNJ-N)
0
0
0
0
0
Your Reaction
Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product
divisions have modest growth. Pharma is its big driver of growth.
Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product
divisions have modest growth. Pharma is its big driver of growth.
Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run.
Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run.
(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.
(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.
He loves it. The judgment against them is not significant. He has a model price of $160.81, a 20% upside. It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.
He loves it. The judgment against them is not significant. He has a model price of $160.81, a 20% upside. It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.
Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.
Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.
Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)
Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)
Comments
00000
